Market Place
Sourcing Support
Y-mAbs & Nobelpharma License DANYELZA® for Japan
04 Nov 2024 //
GLOBENEWSWIRE
Y-mAbs Announces Third Quarter 2024 Conference Call and Webcast
25 Oct 2024 //
GLOBENEWSWIRE
Y-mAbs to Participate in Upcoming Investor Conferences in October
01 Oct 2024 //
GLOBENEWSWIRE
Y-mAbs to Participate in Upcoming Investor Conferences in September
03 Sep 2024 //
GLOBENEWSWIRE
Y-mAbs Reports Q2 2024 Results And Recent Corporate Developments
12 Aug 2024 //
GLOBENEWSWIRE
Y-mAbs to Participate in Upcoming Investor Conferences in August
07 Aug 2024 //
GLOBENEWSWIRE
Y-mAbs Announces Second Quarter 2024 Conference Call and Webcast
05 Aug 2024 //
GLOBENEWSWIRE
Y-mAbs Appoints Peter Pfreundschuh As Chief Financial Officer
01 Jul 2024 //
GLOBENEWSWIRE
Y-mAbs: Preclinical GD2-SADA Data At SNMMI 2024
06 Jun 2024 //
GLOBENEWSWIRE
Eupraxia Pharma: Phase 2 Knee Osteoarthritis Data At EULAR 2024
05 Jun 2024 //
GLOBENEWSWIRE
Y-mAbs` Naxitamab Shows New Phase 2 Interim Analysis At ASCO 2024
01 Jun 2024 //
GLOBENEWSWIRE
Y-mAbs` GD2-SADA Preclinical Data Published At 2024 ASCO Annual Meeting
01 Jun 2024 //
GLOBENEWSWIRE
Y-mAbs Q1 2024 Results and Recent Developments
07 May 2024 //
GLOBENEWSWIRE
Y-mAbs to Announce Q1 2024 Results on May 7
26 Apr 2024 //
GLOBENEWSWIRE
Y-mAbs Therapeutics Naxitamab-gqgk Receives Suppl Approval in the U.S
20 Mar 2024 //
FDA
Y-mAbs Therapeutics Announces Resignation of Chief Financial Officer
14 Mar 2024 //
GLOBENEWSWIRE
Y-mAbs Appoints Executive Mary Tagliaferri, M.D. to its Board of Directors
04 Mar 2024 //
GLOBENEWSWIRE
Y-mAbs Reports Fourth Quarter and Full Year 2023 Financial Results
29 Feb 2024 //
GLOBENEWSWIRE
Y-mAbs to Announce Fourth Quarter and Full Year 2023 Financial Results
16 Feb 2024 //
GLOBENEWSWIRE
Y-mAbs Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference
02 Jan 2024 //
GLOBENEWSWIRE
Y-mAbs Therapeutics Added to the NASDAQ Biotechnology Index
13 Dec 2023 //
GLOBENEWSWIRE
Y-mAbs Reports Third Quarter 2023 Financial Results
13 Nov 2023 //
GLOBENEWSWIRE
Y-mAbs to Announce Third Quarter 2023 Financial and Operating Results
31 Oct 2023 //
GLOBENEWSWIRE
Y-mAbs Names Michael Rossi as President and Chief Executive Officer and Director
18 Oct 2023 //
GLOBENEWSWIRE
Y-mAbs Announces U.S. FDA Clearance of Investigational NDA for CD38-SADA
17 Oct 2023 //
GLOBENEWSWIRE
Y-mAbs Announces Publication in Cancers
16 Oct 2023 //
GLOBENEWSWIRE
Y-mAbs Announces Data to be Presented at the 55th Congress of Pediatric Oncology
21 Sep 2023 //
GLOBENEWSWIRE
Y-mAbs to Participate at Upcoming Investor Conferences in September
06 Sep 2023 //
GLOBENEWSWIRE
Y-mAbs Reports Second Quarter 2023 Financial Results
10 Aug 2023 //
GLOBENEWSWIRE
Y-mAbs to Participate at Upcoming Investor Conferences
02 Aug 2023 //
GLOBENEWSWIRE
Y-mAbs to Announce Second Quarter 2023 Financial Results on August 10, 2023
01 Aug 2023 //
GLOBENEWSWIRE
Y-mAbs Announces Presentation of Naxitamab Data at ASCO
26 May 2023 //
GLOBENEWSWIRE
Y-mAbs Announces Presentation of GD2-SADA Study at ASCO
26 May 2023 //
PRESS RELEASE
Y-mAbs DANYELZA for the Treatment of High-Risk Neuroblastoma approved in Brazil
23 May 2023 //
GLOBENEWSWIRE
Y-mAbs Reports 1Q 2023 FYR and Recent Corporate Developments and Updates 2023
08 May 2023 //
GLOBENEWSWIRE
Y-mAbs Announces Presentation of Naxitamab data at AACR
18 Apr 2023 //
GLOBENEWSWIRE
Y-mAbs Announces First Patient Dosed in Phase 1 Clinical Trial of GD2-SADA
05 Apr 2023 //
GLOBENEWSWIRE
Y-mAbs Reports 4Q and Reports Full 2022 FYR and Recent Corporate Developments
30 Mar 2023 //
GLOBENEWSWIRE
Y-mAbs to Announce 2022 Financial and Operating Results on March 30, 2023
21 Mar 2023 //
GLOBENEWSWIRE
Y-mAbs and EMA Reach Agreement on the Pediatric Investigation Plan for Naxitamab
02 Feb 2023 //
GLOBENEWSWIRE
Y-mAbs Announces Restructuring Plan and Provides Financial Outlook
04 Jan 2023 //
GLOBENEWSWIRE
Y-mAbs Therapeutics to Present at 41st Annual J.P. Morgan Healthcare Conference
03 Jan 2023 //
GLOBENEWSWIRE
Y-mAbs Announces Partnership Regarding Early Access Program for DANYELZA
21 Dec 2022 //
GLOBENEWSWIRE
The CHMP has Adopted a Negative Opinion for Omburtamab for the Treatment of CNS
16 Dec 2022 //
GLOBENEWSWIRE
Y-mAbs Announces Pipeline Update
14 Dec 2022 //
GLOBENEWSWIRE
Y-mAbs’ DANYELZA® for the Treatment of High-Risk Neuroblastoma Approved in China
08 Dec 2022 //
GLOBENEWSWIRE
Y-mAbs to Host Annual Research and Development Day in New York
06 Dec 2022 //
GLOBENEWSWIRE
U.S. FDA declines to approve Y-mAbs`s pediatric cancer drug
02 Dec 2022 //
HEALTH ET
Y-mAbs Announces Complete Response Letter for Omburtamab BLA
01 Dec 2022 //
GLOBENEWSWIRE
Y-mAbs Reports 3Q 2022 Financial Results and Recent Corporate Developments
07 Nov 2022 //
GLOBENEWSWIRE
Y-mAbs to Announce3Q 2022 Financial & Operating Results on Nov 7, 2022
02 Nov 2022 //
PRESS RELEASE
Y-mAbs` rare disease drug roundly rejected by FDA AdComm over weakness
01 Nov 2022 //
FIERCEBIOTECH
Y-mAbs Announces Outcome of FDA Advisory Committee Meeting on Omburtamab
29 Oct 2022 //
GLOBENEWSWIRE
Y-mAbs Announces Pivotal Data for Omburtamab
03 Oct 2022 //
GLOBENEWSWIRE
Y-mAbs Announces Regulatory Filing for DANYELZA® (naxitamab-gqgk) in Brazil
26 Sep 2022 //
GLOBENEWSWIRE
Y-mAbs lands an FDA adcomm for its 2nd neuroblastoma treatment
03 Sep 2022 //
ENDPTS
Y-mAbs Announces Scheduling of FDA Advisory Committee Meeting for Omburtamab
01 Sep 2022 //
GLOBENEWSWIRE
Y-mAbs and Takeda Announces Marketing Authorization in Israel for DANYELZA
30 Aug 2022 //
GLOBENEWSWIRE
Y-mAbs Announces Q2 Financial Results and Recent Corporate Developments
08 Aug 2022 //
GLOBENEWSWIRE
Y-mAbs to Announce Second Quarter 2022 Financial Results
02 Aug 2022 //
GLOBENEWSWIRE
